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Purpose/Objective: Dose-painting by numbers (DBPN) is gaining 
interest and has the potential to improve tumor local control with 
minimal increase of side effects. Because of the voxel-by-voxel non-
uniform dose prescription in DPBN, usual margin recipes to account 
for geometric and random uncertainties do not apply. Robust 
treatment plans may be achieved by incorporating geometric 
uncertainties during plan optimization. Although powerful, this 
method is not available in most treatment planning systems (TPS) and 
may be time-consuming. Our approach aims at providing a universal 
solution (i.e. TPS independent), by including systematic and random 
geometric uncertainties implicitly in the prescription for DPBN. 
Materials and Methods: We propose here a method that modifies the 
heterogeneous dose prescription DP to ensure robustness of planned 
dose DPlanned against standard deviations of systematic errors Σ and 
random errors σ. The prescription is based in this study on FDG-PET 
images with an escalation from 70 to 86 Gy. The objective was that 
95% of all voxels in the GTVPET received at least 95% of their respective 
prescribed dose even in the presence of geometric errors (Q0.95>95%). 
The prescription DP was modified by a morphological dilation of αΣ 
and a deconvolution by σ (assuming Gaussian distribution). The GTVPET 
was also extended by αΣ, to generate a PTVPET volume. For a 90% 
confidence interval, α=2.5. The planning process was performed on a 
TomoTherapy system such that 95% of the points within PTVPET 
received at least 95% of the modified prescription (Q0.95>95%) and less 
than 5% of the points received more than 105% of the modified 
prescription (quality factors Q0.95 and Q1.05 are derived from the 
cumulative quality volume histograms, the quality factor Q being the 
ratio in each CT voxel between the planned dose and the prescribed 
dose). Robustness was evaluated by translating and blurring DPlanned 
and by comparing the resulting dose with the unmodified dose 
prescription within GTVPET. The methodology was illustrated for two 
head-and-neck tumors treated by helical TomoTherapy.  
Results: For both patients, the TomoTherapy system was capable to 
reproduce modified non-uniform prescriptions with Q0.95>95% and 
Q1.05<5%. Coverage was preserved when systematic and random 
displacements were smaller than αΣ and σ. For larger displacements, 
coverage was degraded. The figure illustrates two examples for one 
patient. In figure (a), no correction of the prescription was 
performed, leading to significant underdosage when geometric errors 
were simulated (down to 62.8% for Q0.95). In figure (b) target coverage 
was preserved even in the presence of geometric errors. 
 
 Conclusions: The method generates treatment plans that are robust 
against geometric uncertainties without the need to handle geometric 
errors in the optimizer of the TPS. The methodology was illustrated 
for head-and-neck but is potentially general for all tumor sites.  
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Purpose/Objective: With ion therapy it is possible to deposit dose 
very precisely, however it is still more sensitive to setup errors, 
interfractional and intrafractional movements than traditional photon 
therapy. When physicists create treatment plans, angle selection is 
solely governed by their intuition and experience. Here, we present a 
model which within seconds can quantify angle quality from CT images 
and structure information for use selection of robust beam 
orientations. 
Materials and Methods: The model creates a 2D grid orthogonal to the 
beam axis at the isocenter. The outer contour of the PTV is projected 
on the grid and the water equivalent path length (WEPL) along the 
particle trajectories are calculated in each pixel of the grid. The 
robustness quality factor (RQF) is determined as 10 minus the mean 
sum of squares of the WEPL pixel-to-pixel variations, i.e. the 
maximum value of 10 represents a perfectly robust plan. A CT scan of 
a tumour of pituitary gland is used for validation of the model. The 
robustness quality factor is then mapped for the entire angular space 
covered by the gantry and couch. Islands of good, intermediate and 
poor angels can be identified, and 15 angles are selected from these 
regions. The 15 angles are then used as validation points for the 
model, in terms of systematic and random errors. The field is 
optimised so the mean dose is 100% in PTV using the treatment 
planning system TRiP. The resulting plan is then shifted with 
systematic offsets along the lateral direction of the beam, and the 
RQF is determined. All recalculations and data analysis are done by 
PyTRiP. For evaluating the plan against systematic setup errors we 
score the V-95% of CTV and evaluate an average setup offset for which 
the 2% of the CTV get less than 95% of prescribed dose. For random 
errors a new dose distribution is generated by adding the dose 
distributions sets with varying offset and weighting them with a 
Gaussian distribution centered at zero offset. In the summed dose 
distribution, the V-95% of CTV is calculated and used directly as a 
quality estimator for the plan. 
Results: For the random error analysis, the V-95% of CTV depends 
slightly on RQF. Values close to 10 (i.e. robust plans) turns out to give 
good coverage, and vice versa. However, angles with intermediate 
RQF show no clear behavior. For systematic errors there a 
straightforward dependency on the RQF can be observed. For a PTV 
with a margin of 4 mm and a robustness quality factor of 5, then the 
mean offset to underdose 2% of the tumour is in the order of 1 mm or 
below. For a quality factor of 9, this is in the order of 2.5 mm. 
 
Conclusions: We have succeeded to create a model which can 
quantify the quality of a chosen beam angle against positioning offset 
errors. The quality is represented by the RQF, and its validity was 
checked against systematic and random errors. We demonstrate that 
RQF is a good representation of the robustness against positioning 
errors. However, tests on additional patient cases may still be 
needed. 
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Purpose/Objective: For patients with metal hip implants AAPM 
taskgroup 63 recommends avoidance of beams that deliver dose to the 
target while first (in part) passing through the implant. Especially for 
patients with bilateral prostheses, this severely limits the search 
space for beam angle selection, generally resulting in less favorable 
dose distributions since primarily only anterior and posterior beams 
can be selected. In this study, we compared this approach with an 
alternative strategy. 
Materials and Methods: All plans were generated fully automatically 
(i.e., no human trial-and-error interactions) using iCycle, our in-house 
developed algorithm for multicriterial optimization of beam angles 
and fluence profiles, allowing objective comparisons of planning 
strategies. For 18 prostate cancer patients (8 with bilateral hip 
prostheses, 10 with a right-sided unilateral prosthesis), two planning 
strategies were evaluated: i) full exclusion of beams containing 
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beamlets that would deliver dose to the target after passing a 
prosthesis (IMRTremove, recommended by AAPM), and ii) exclusion of 
only those beamlets including a 5 mm margin (IMRTcut). Plans with 
optimized coplanar and non-coplanar beam arrangements were 
generated. Differences in PTV coverage and sparing of organs at risk 
(OARs) were quantified. The impact of beam number on plan quality 
was evaluated. 
Results: Especially for patients with bilateral hip prostheses, IMRTcut 
significantly improved rectum and bladder sparing compared to 
IMRTremove. For 9-beam coplanar plans, rectum V60Gy reduced by 17.5% 
± 15.0% (maximum 37.4%, p = 0.036) and rectum Dmean by 9.4% ± 7.8% 
(maximum 19.8%, p = 0.036). PTV coverage was similar, except for 
one patient who had a V95% of only 22.3% for IMRTremove, compared to 
99.1% for IMRTcut. Improved PTV coverage was only possible with a 
higher dose in all OARs (see figure). Further improvements in OAR 
sparing were achieved by using non-coplanar beam set-ups, reducing 
rectum V60Gy by another 4.6% ± 4.9% (p = 0.012) for non-coplanar 9-
beam IMRTcut plans. Large reductions in rectum dose delivery were 
also observed when increasing the number of optimized beam 
directions in the plans. For bilateral implants, rectum V60Gy was 37.3% 
± 12.1% for coplanar 7-beam IMRTcut plans which reduced on average 
by 13.5% (maximum 30.1%, p = 0.012) for 15 optimized beam 
directions. 
Conclusions: For prostate cancer patients with metal hip implants, 
iCycle was able to automatically generate high quality, patient-
specific IMRT plans with optimized coplanar or non-coplanar beam 
arrangements. Excluding only beamlets that would deliver dose to the 
PTV after passing through a prosthesis significantly improved OAR 
sparing for patients with bilateral implants as opposed to the AAPM 
taskgroup 63 recommendation. Non-coplanar beam arrangements and, 
to a larger extent, increasing the number of optimized treatment 
beams further improved plan quality. 
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Purpose/Objective: Stereotactic body radiotherapy (SBRT) for non-
small-cell lung cancer (NSCLC) has led to promising local control and 
overall survival for fractionation schemes with increasingly high 
fractional doses. A point has however been reached where too few 
fractions may be used to allow efficient inter-fraction reoxygenation 
(IFR) of the hypoxic cells possibly residing in the tumours. It was the 
purpose of this study to investigate the impact of hypoxia and 
extreme hypofractionation on the tumour control probability (TCP) 
using realistic 3D-models of tumour oxygenation. 
Materials and Methods: 3D-models of tumour oxygenation have been 
based on previous calculations of tumour oxygenation at cellular level 
for various distributions of intervascular distances. The models took 
into account dynamic changes in the oxygenation of the tumours 
between fractions. Simulations were performed for currently used 
fractionation schemes for NSCLC and for theoretical dose prescriptions 
that may be used in SBRT. Clinically relevant dose distributions were 
used to ensure the fulfilment of prescription details for dose 
escalation, dose to the PTV periphery and maximum dose. Cellular 
response was assessed with the LQ model at voxel level and a Poisson 
TCP model at tumour level. 
Results: Calculated tumour control probabilities with IFR agree best 
with reported clinical local control for multi-fraction schemes (Table 
1). The largest disagreement between the clinical figures and the 
calculated values are seen for the single-fraction schemes which could 
be caused by other biophysical processes believed to take place at 
high doses, but not included in the model, such as vascular 
endothelial apoptosis.TCP curves for 1, 3 and 5 fractions with and 
without IFR (Figure 1) demonstrate the importance of allowing for IFR. 
Furthermore, they suggest that 3 or 5 fractions are enough to ensure 
IFR. 
 
Table 1. Examples of calculated TCP with and without IFR for the 
dose schemes pertinent to current clinical practice in the SBRT 
treatment of NSCLC with clinical figures of survival and local control. 
Normal- and tumour tissue BED:s are also given.  
 
† Dose range 24-40 Gy, 69% was given 37.5Gy  
‡ Based on 60 Gy totaldoses given in 3, 5 and 8 fractions: 3x20 
Gy(33%), 5x12 Gy (50%), 8x7.5 Gy(17%) 
 
 
 
Conclusions: Single-fraction stereotactic treatments may require a 
considerable increase in dose per fraction, well above fractional doses 
used today, to counteract the radioresistance of hypoxic cells. 
Although attractive from an economical and practical viewpoint, 
extreme hypofractionation in SBRT should therefore be pursued with 
caution as the reduced possibility for IFR may result in impaired local 
control.  
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Purpose/Objective: One of the worst radiation induced acute effects 
in treating head-and-neck (HN) cancer is grade 3 or higher acute (oral 
and pharyngeal) mucosal toxicity(AMT), caused by the killing/ 
depletion of mucosa cells. Late toxicity are reported after altered 
radiotherapy schedules. The paper aims attesting a predictive model 
of the AMT, as well as late toxicity, in HN cancer patients receiving 
different radiotherapy schedules. 
Materials and Methods: Various radio-therapeutic schedules have 
been reviewed and classified as tolerable or intolerable based on AMT 
 
Dose 
prescr. 
BED3 
(Gy3) 
BED10 
(Gy10) 
Treatment outcome TCP (%) 
Overall 
suvival 
Local 
control 
No 
reox IFR 
3x12.5 
Gy, 
60% 
isodose 
193.8 84.4 
80% at 1 
year† 
75% at 2 
years† 
100% at 1 
year† 
87% at 2 
years† 
10 99 
5x10 Gy,
80% 
isodose 
216.7 100.0 
90/63% at 3 
years 
(Stage 
1A/1B) 
93/96% at 3 
years 
(Stage 
1A/1B) 
0 99 
8x7.5 Gy,
80% 
isodose 
210.0 105.0 
85.7% at 1 
year‡ 
54% at 2 
years‡ 
45.1% at 3 
years‡ 
89% at 3 
years‡ 0 100
